Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments
Abstract Background Antipsychotic drugs are associated with adverse events, but serious side effects are not frequent. This study aimed to ascertain whether previous exposure to antipsychotic treatment was associated with metabolic disturbances induced by current antipsychotic medication. Methods A...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-03-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-022-03853-y |
| _version_ | 1818358485594669056 |
|---|---|
| author | Ye Yang Peng Xie Yujun Long Jing Huang Jingmei Xiao Jingping Zhao Weihua Yue Renrong Wu |
| author_facet | Ye Yang Peng Xie Yujun Long Jing Huang Jingmei Xiao Jingping Zhao Weihua Yue Renrong Wu |
| author_sort | Ye Yang |
| collection | DOAJ |
| description | Abstract Background Antipsychotic drugs are associated with adverse events, but serious side effects are not frequent. This study aimed to ascertain whether previous exposure to antipsychotic treatment was associated with metabolic disturbances induced by current antipsychotic medication. Methods A total of 115 antipsychotic-naïve patients, 65 patients with previous exposure to low-metabolic-risk antipsychotics, and 88 patients with previous exposure to high-metabolic-risk antipsychotics were enrolled in our case-control study. All patients were administered olanzapine. Body weight, body mass index (BMI), biochemical indicators of blood glucose and lipids, the proportion of patients who gained more than 7% of their body weight at baseline, and the percentage of dyslipidemia were evaluated. All assessments were conducted at baseline and at 4 and 6 weeks after treatment. Results Olanzapine treatment resulted in a significant increase in body weight and BMI in antipsychotic-naïve patients compared with the other two groups (both p < 0.05). However, increases in lipid levels in the high-metabolic-risk antipsychotics group were significantly higher than that in the other two groups (both p < 0.05). A history of antipsychotics use was not associated with weight gain (all p > 0.05). Higher low-density lipoprotein cholesterol ≥3.37 mmol/L–1 was observed in antipsychotics exposure group compared with no history of antipsychotics exposure (aOR, 1.75; 95% CI, 1.07-3.52). Particularly, a history of high-metabolic-risk antipsychotics use was associated with a higher risk of LDL-C ≥3.37 mmol/L–1(aOR, 2.18; 95% CI, 1.03-3.32) compare with other two groups. Conclusions A history of exposure to antipsychotics, particularly high-metabolic-risk antipsychotics, is associated with current antipsychotic-induced metabolic disturbances. |
| first_indexed | 2024-12-13T20:29:45Z |
| format | Article |
| id | doaj.art-5e613a9c80c842dd8587db2e385eb14e |
| institution | Directory Open Access Journal |
| issn | 1471-244X |
| language | English |
| last_indexed | 2024-12-13T20:29:45Z |
| publishDate | 2022-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj.art-5e613a9c80c842dd8587db2e385eb14e2022-12-21T23:32:28ZengBMCBMC Psychiatry1471-244X2022-03-0122111310.1186/s12888-022-03853-yPrevious exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatmentsYe Yang0Peng Xie1Yujun Long2Jing Huang3Jingmei Xiao4Jingping Zhao5Weihua Yue6Renrong Wu7Department of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South UniversityDepartment of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South UniversityDepartment of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South UniversityDepartment of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South UniversityDepartment of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South UniversityDepartment of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South UniversityPeking University Sixth Hospital/Institute of Mental HealthDepartment of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South UniversityAbstract Background Antipsychotic drugs are associated with adverse events, but serious side effects are not frequent. This study aimed to ascertain whether previous exposure to antipsychotic treatment was associated with metabolic disturbances induced by current antipsychotic medication. Methods A total of 115 antipsychotic-naïve patients, 65 patients with previous exposure to low-metabolic-risk antipsychotics, and 88 patients with previous exposure to high-metabolic-risk antipsychotics were enrolled in our case-control study. All patients were administered olanzapine. Body weight, body mass index (BMI), biochemical indicators of blood glucose and lipids, the proportion of patients who gained more than 7% of their body weight at baseline, and the percentage of dyslipidemia were evaluated. All assessments were conducted at baseline and at 4 and 6 weeks after treatment. Results Olanzapine treatment resulted in a significant increase in body weight and BMI in antipsychotic-naïve patients compared with the other two groups (both p < 0.05). However, increases in lipid levels in the high-metabolic-risk antipsychotics group were significantly higher than that in the other two groups (both p < 0.05). A history of antipsychotics use was not associated with weight gain (all p > 0.05). Higher low-density lipoprotein cholesterol ≥3.37 mmol/L–1 was observed in antipsychotics exposure group compared with no history of antipsychotics exposure (aOR, 1.75; 95% CI, 1.07-3.52). Particularly, a history of high-metabolic-risk antipsychotics use was associated with a higher risk of LDL-C ≥3.37 mmol/L–1(aOR, 2.18; 95% CI, 1.03-3.32) compare with other two groups. Conclusions A history of exposure to antipsychotics, particularly high-metabolic-risk antipsychotics, is associated with current antipsychotic-induced metabolic disturbances.https://doi.org/10.1186/s12888-022-03853-yAntipsychoticMetabolic side effectsSchizophreniaSide effectsWeight |
| spellingShingle | Ye Yang Peng Xie Yujun Long Jing Huang Jingmei Xiao Jingping Zhao Weihua Yue Renrong Wu Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments BMC Psychiatry Antipsychotic Metabolic side effects Schizophrenia Side effects Weight |
| title | Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments |
| title_full | Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments |
| title_fullStr | Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments |
| title_full_unstemmed | Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments |
| title_short | Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments |
| title_sort | previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments |
| topic | Antipsychotic Metabolic side effects Schizophrenia Side effects Weight |
| url | https://doi.org/10.1186/s12888-022-03853-y |
| work_keys_str_mv | AT yeyang previousexposuretoantipsychoticdrugtreatmentisaneffectivepredictorofmetabolicdisturbancesexperiencedwithcurrentantipsychoticdrugtreatments AT pengxie previousexposuretoantipsychoticdrugtreatmentisaneffectivepredictorofmetabolicdisturbancesexperiencedwithcurrentantipsychoticdrugtreatments AT yujunlong previousexposuretoantipsychoticdrugtreatmentisaneffectivepredictorofmetabolicdisturbancesexperiencedwithcurrentantipsychoticdrugtreatments AT jinghuang previousexposuretoantipsychoticdrugtreatmentisaneffectivepredictorofmetabolicdisturbancesexperiencedwithcurrentantipsychoticdrugtreatments AT jingmeixiao previousexposuretoantipsychoticdrugtreatmentisaneffectivepredictorofmetabolicdisturbancesexperiencedwithcurrentantipsychoticdrugtreatments AT jingpingzhao previousexposuretoantipsychoticdrugtreatmentisaneffectivepredictorofmetabolicdisturbancesexperiencedwithcurrentantipsychoticdrugtreatments AT weihuayue previousexposuretoantipsychoticdrugtreatmentisaneffectivepredictorofmetabolicdisturbancesexperiencedwithcurrentantipsychoticdrugtreatments AT renrongwu previousexposuretoantipsychoticdrugtreatmentisaneffectivepredictorofmetabolicdisturbancesexperiencedwithcurrentantipsychoticdrugtreatments |